This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Peregrine Pharma Stock Craters on Lung Cancer Drug Blowup

TUSTIN, Calif. ( TheStreet) -- Peregrine Pharmaceuticals (PPHM - Get Report) threw out previously reported results -- including the survival benefit -- from a mid-stage study of its lung cancer drug bavituximab because of "major discrepancies" in the study's conduct, the company said Monday.

Shares of Peregrine plunged $3.89 , or 72%, to $1.48 in early trading. The stock has now given back nearly all its gains of the summer, driven by speculation and hype around the bavituximab lung cancer data.

During the course of preparing for a meeting with the U.S. Food and Drug Administration, Peregrine says it discovered differences between the results reported for some patients and their "treatment code assignments" -- whether or not patients were being treated with bavituximab or a placebo.

Peregrine blamed the problem on an undisclosed, independent contractor hired to help run the clinical study. As a result, "investors should not rely on clinical data that the company disclosed on or before Sept. 7, 2012 from its phase II bavituximab trial in patients with second-line non-small cell lung cancer or any presentations or other documents related to this phase II trial," Peregrine said.

The bavituximab lung cancer data were already controversial even before Monday's disclosure of study misconduct.

The combination of bavituximab and docetaxel purported to yield a median overall survival of 12.1 months compared to 5.6 months for patients treated with docetaxel and a placebo. But Peregrine conducted half the study in India and Eastern Europe -- geographies with bad reputations for producing overly positive results that cannot be reproduced in larger, confirmatory clinical trials.

The median overall survival of 5.6 months in the study's docetaxel control arm also raised eyebrows for being unusually low, thereby making the observed bavituximab clinical benefit appear stronger than it might actually be.

Peregrine was hoping to sign a partner to help develop bavituximab and begin a phase III study in lung cancer by the middle of next year. Monday's setback changes all that. Now, the future of bavituximab and Peregrine are both in jeopardy.

If the bavituximab data are found to be fraudulent, Peregrine's lenders may find the company in default and seek immediate repayment of the $15 million granted in late August.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PPHM $0.37 -4.90%
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs